A Study to Evaluate Efficacy and Safety of PTC299 (Emvododstat) in Hospitalized Participants With Coronavirus (COVID-19)
Study sponsor: PTC Therapeutics
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2022-07-20Actual
Enrollment · participants189Actual
Source updated2023-06-26Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.